| Property | Value |
|---|
|
?:abstract
|
-
There is concern that people with rheumatic disease, often treated with immunosuppressive or immunomodulatory medication, may be at increased risk of poor outcomes of novel coronavirus disease-2019 (COVID-19). However, hyperinflammation is a major cause of morbidity and mortality in COVID-19 and treatment with glucocorticoids has been shown to improve outcomes in patients with severe COVID-19. Therefore, uncertainty exists about continuing or withholding immune therapies with risk of infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This review covers the current knowledge with respect to risk of infection, and outcomes and risk factors for poor outcomes in patients with rheumatic disease. We also discuss data from other immune mediated diseases and its relevance to patients with rheumatic disease. In addition, we cover the limitations of the research efforts to date and how the current knowledge translates into practice guidance. Finally, we discuss our vision of the future research agenda.
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
-
10.1016/j.berh.2020.101657
|
|
?:journal
|
-
Best_Pract_Res_Clin_Rheumatol
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/9b1d5f763c929b6d411ff62d7767a7d65571da08.json
|
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7756169.xml.json
|
|
?:pmcid
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: epidemiology & outcomes
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}